This joint-specific response pattern was consistent across all advanced treatment modalities, including abatacept, interleukin-6 receptor inhibitors, Janus kinase inhibitors, rituximab and TNFi.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results